Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Six months ended June 30, 2021
Filing Date: August 26, 2021
Context: The filing incorporates by reference a press release, an Operating and Financial Review, and unaudited interim condensed consolidated financial statements. The report covers financial results and updates on drug development programs.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index for the Form 6-K. It references the existence of financial statements (Exhibit 99.2) and an Operating and Financial Review (Exhibit 99.1) but does not contain specific numerical values for the following metrics within this document:
- Revenue
- Net Profit/Loss
- Cash Flow
- Profit Margins
- Debt Levels
- Liquidity Position
Investors must refer to the attached exhibits (99.1, 99.2, and 99.3) for specific financial data.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. It only confirms that financial results for the six months ended June 30, 2021, were announced.
Guidance, Outlook, and Risks
Outlook and Updates: The press release (Exhibit 99.3) includes updates on the Company's drug development programs and forward-looking statements.
Risks and Contingencies: The text notes the inclusion of "Forward-Looking Statements" in the press release but does not detail specific risks or contingencies in this summary document.
Key Facts for Investor Verification
- Verify the specific revenue and cash burn rates in the unaudited interim condensed consolidated financial statements (Exhibit 99.2).
- Review the "Operating and Financial Review and Prospects" (Exhibit 99.1) for management's analysis of the six-month period.
- Examine the press release (Exhibit 99.3) for specific milestones or setbacks in drug development programs.
- Confirm the company's liquidity runway based on the cash position reported in the June 30, 2021, financial statements.